CN111116647B - Phosphoric acid compound with HDAC (Histone deacetylase) inhibitory activity as well as preparation method and application thereof - Google Patents
Phosphoric acid compound with HDAC (Histone deacetylase) inhibitory activity as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN111116647B CN111116647B CN201911213773.7A CN201911213773A CN111116647B CN 111116647 B CN111116647 B CN 111116647B CN 201911213773 A CN201911213773 A CN 201911213773A CN 111116647 B CN111116647 B CN 111116647B
- Authority
- CN
- China
- Prior art keywords
- compound
- inhibitory activity
- hdac
- ethyl acetate
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
A phosphate compound with HDAC inhibitory activity, and its preparation method and application are provided. The invention belongs to the technical field of medicines, and provides a phosphoric acid compound shown in a formula (I), or a conformational isomer thereof, or an optical isomer thereof. Formula I:
Description
Technical Field
The invention relates to a phosphate compound with HDAC (histone deacetylase) inhibitory activity, and a preparation method and application thereof.
Background
Histone Deacetylase (HDAC) is a key enzyme for catalyzing the removal of acetyl group of lysine residue in histone and non-histone, and plays an important role in gene transcription, cell cycle progression, apoptosis, tumorigenesis, etc. Eyes of a userPreviously, HDACs were abnormally high expressed in a variety of diseases, such as tumors. Therefore, the HDAC targeted therapy is expected to become an effective therapeutic method, and the HDAC inhibitor is expected to be developed into a disease targeted therapeutic agent. Several hundred HDAC inhibitors (HDACi) have been designed and synthesized, and their structures are abundant, but HDACi is Zn2+Dependent form thereof with Zn2+The chelating types of (1) are mainly classified into four types: the first class, hydroxamic acids, represents the drug SAHA (approved for marketing in 2006); the second, cyclotetrapeptide, represents the drug Romidepsin (approved for marketing in 2009); the third class, the benzamides, represents the inhibitor Chidamide (marketed in 2014); the fourth class, fatty acids, represents inhibitors such as Valproic acid (phase III clinical trial) and the like.
Of these inhibitors, the HDACi activity of hydroxamic acid is generally greater than that of other types. However, the hydroxamic acids HDACi are unstable in vivo and are easily metabolized into toxic substances; furthermore, most HDACis are now a broad spectrum of HDACs, which are taken up and distributed widely among the various HDAC isoforms in the tissues, and this lack of selectivity often results in undesirable side effects such as fatigue, thrombocytopenia, nausea/vomiting and cardiotoxicity, due to the different isoforms' functions. Clinical data have shown that SAHA can cause neurotoxicity of thrombus formation, and FK228 has cardiotoxicity. These disadvantages severely limit the widespread clinical use of HDACis. Therefore, the development of new-structure, high-efficiency and low-toxicity HDACi is an urgent task.
Disclosure of Invention
In order to solve the above problems, the present invention provides a phosphate compound having HDAC inhibitory activity, and preparation thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a compound of formula I:
formula I
Wherein R is H, Me, OMe, F.
The invention also aims at the application of the compound or the isomer thereof in preparing HDAC inhibitor medicines.
The HDAC inhibitor medicine is used for treating diseases caused by abnormal activity of HDAC.
Further, the disease is any one or more of cell proliferation disease, autoimmune disease, inflammation, neurodegenerative disease, and viral disease.
Still further, the disease is cancer.
A pharmaceutical composition for inhibiting histone deacetylase activity is a preparation prepared by taking the compound or crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
The present invention also provides a method for preparing a phosphate compound having HDAC inhibitory activity represented by the above structural formula I, comprising the steps of:
(1) dissolving aniline or its derivatives (p-toluidine, p-methoxyaniline, p-fluoroaniline) and 6-heptenoic acid in dichloromethane, and adding 2- (7-azobenzotriazol)N,N,N',N' -tetramethyluronium Hexafluorophosphate (HATU) and N, N-Diisopropylethylamine (DIEA), stirred at room temperature for 12 hours; after the reaction was complete, saturated NaHCO was added3Solution, dichloromethane extraction, anhydrous Na2SO4Drying, evaporating to remove dichloromethane to obtain crude product, and purifying by column chromatography to obtain compound 3a (orN-phenyl-6-heptenylamine), 3b (NP-tolyl-6-heptenylamine), 3c (N-p-methoxyphenyl-6-heptenylamine), 3d (N-p-fluorophenyl-6-heptenylamine); the mass ratio of aniline or its derivative, 6-heptenoic acid, HATU and DIEA is 1: 1.2: 1.3: 3.
(2) Dissolving the compound 3a, 3b, 3c or 3d inN,N-Dimethylformamide (DMF), K is added2CO3And dibenzyl phosphite, heating to 50 ℃ and reacting for 2 hours; after the reaction was completed, 5% citric acid solution and ethyl acetate were addedExtracted with anhydrous Na2SO4Drying, evaporating to remove ethyl acetate to obtain crude product, and purifying by column chromatography to obtain (7-oxo-7-anilino) heptyl dibenzyl phosphate compounds 4a, 4b, 4c or 4 d; compounds 3a, 3b, 3c or 3d with K2CO3And the mass ratio of dibenzylphosphite is 1: 2: 1.6.
(3) Mixing (7-oxo-7-anilino) heptyl dibenzyl phosphate compounds 4a, 4b, 4c or 4d and 6M HCl, and heating to 50 ℃ for reaction for 12 hours; distilling under reduced pressure to remove newly generated methanol, adding 6M HCl, heating to 50 deg.C for reaction for 12 hr, distilling under reduced pressure to remove newly generated methanol, extracting with ethyl acetate, and extracting with anhydrous Na2SO4Drying, evaporating to remove ethyl acetate to obtain crude product, and purifying by column chromatography to obtain (7-oxo-7-anilino) heptyl phosphate compounds 5a, 5b, 5c or 5 d; the mass ratio of the (7-oxo-7-anilino) heptyl dibenzyl phosphate compound to the 6M hydrochloric acid was 1: 1.7.
The reaction flow is as follows:
the phosphate compound with HDAC inhibitory activity has stronger inhibitory activity on HDAC enzyme.
The obtained phosphoric acid compound with HDAC inhibitory activity has strong inhibitory activity on breast cancer MCF-7 and MDA-MB-231 cells, and has no toxicity on normal breast epithelial cells MCF-10A.
Compared with the prior art, the invention has the beneficial effects that:
(1) the inhibitors of the invention bind zinc ions in the active pocket of HDAC enzymes using phosphate as a chelating group, unlike conventional hydroxamic acid, benzamide chelating groups. Thus, phosphate compounds are a novel class of HDAC inhibitors.
(2) The inhibitors of the invention are not toxic to normal mammary epithelial cells.
(3) The preparation method provided by the invention is simple, mild in condition and high in yield, provides a new drug research and development idea, improves the utilization efficiency and treatment effect of the drug for treating cancer, and has a remarkable effect on inhibiting solid tumors.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It is to be understood that the described embodiments are merely a few embodiments of the invention and not all embodiments thereof. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making innovative efforts, fall within the scope of protection of the present invention.
Example 1: preparation of (7-oxo-7-anilino) heptyl phosphate (5a)
The chemical structure of (7-oxo-7-anilino) heptyl phosphate (5a) in this example is as follows:
the synthetic route of 5a in this example is as follows:
Nsynthesis of (3a) phenyl-6-heptenamine
Aniline (502.9 mg, 5.4 mmol) and 6-heptenoic acid (833.1 mg, 6.5 mmol) were dissolved in dichloromethane, followed by addition of 2- (7-azobenzotriazole) -N,N,N',N' -tetramethyluronium hexafluorophosphate (HATU, 2.662 g, 7.0 mmol) andN,Ndiisopropylethylamine (DIEA, 2.094 g, 16.2 mmol), stirred at room temperature for 12 h; after the reaction was complete, 25 mL of saturated NaHCO was added3Solution, dichloromethane (3X 10 mL) extraction, anhydrous Na2SO4Drying and evaporation of dichloromethane gave the crude product which was purified by column chromatography to give 602.7 mg of compound 3a in 54.9% yield.
Synthesis of dibenzyl (4a) phosphate (7-oxo-7-anilino) heptyl
Will be provided withN-phenyl-6-heptenamine Compound 3a (406.6 mg, 2.0 mmol) was dissolved inN,N-dimethylformamide (DMF, 10 mL), K was added2CO3(552.8 mg, 4.0 mmol) and dibenzylphosphite (839.2 mg, 3.2 mmol) were heated to 50 ℃ for 2 hours; after the reaction was complete, 5% citric acid solution (15 mL) was added, and the mixture was extracted with ethyl acetate (3X 20 mL) and anhydrous Na2SO4Drying, evaporating to remove ethyl acetate to obtain crude product, and purifying by column chromatography to obtain 452.2 mg of compound 4a with yield of 48.6%.
Synthesis of (7-oxo-7-anilino) heptyl phosphate (5a)
(7-oxo-7-anilino) heptyl dibenzyl phosphate 4a (558.6 mg, 1.2 mmol) and 6M HCl (6 mL) were mixed and heated to 50 ℃ for 12 hours; distilling under reduced pressure to remove newly generated methanol, adding 6M HCl (6 mL), heating to 50 deg.C for reaction for 12 hr, distilling under reduced pressure to remove newly generated methanol, extracting with ethyl acetate, and extracting with anhydrous Na2SO4Drying, removing ethyl acetate by evaporation to obtain a crude product, and purifying by column chromatography to obtain 279 mg (7-oxo-7-anilino) heptyl phosphate 5a with a yield of 81.5%.1HNMR (400 M, CDCl3) δ7.55 (d, J = 7.6 Hz, 2H), 7.35 (t, J = 8.0 Hz, 2H), 7.11-7.18 (m, 1H), 2.40 (t, J = 7.2 Hz, 2H), 1.75-1.83 (m, 4H), 1.61-1.65 (m, 2H), 1.54 (d, J = 6.8 Hz, 4H). 13CNMR (100 M, CDCl3) δ171.27, 137.94, 128.97, 124.26, 119.95, 58.65, 40.00, 37.46, 26.31, 25.40, 25.02.
Example 2: synthesis of [ 7-oxo-7- (4-methylanilino) ] heptyl phosphoric acid (5b)
The procedure is as in example 1, wherein the aniline is replaced by p-toluidine and the product is a white solid with a yield of 83.4%.1HNMR (400 M, CDCl3) δ7.41 (d, J = 8.8 Hz, 2H), 7.07 (s, 1H), 6.86 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H), 2.35 (t, J = 7.2 Hz, 2H), 1.72-1.78 (m, 2H), 1.52 (d, J = 6.8 Hz, 4H) 1.25-1.33 (m, 4H).
Example 3: synthesis of [ 7-oxo-7- (4-methoxyanilino) ] heptyl phosphoric acid (5c)
The procedure is as in example 1, wherein aniline is replaced by p-anisidine, and the product is a white solid with a yield of 86.2%.1HNMR (400 M, CDCl3) δ7.39 (d, J = 8.4 Hz, 2H), 7.24 (s, 1H), 7.12 (d, J= 8.0 Hz, 2H), 2.35 (t, J = 7.2 Hz, 2H), 2.30 (s, 3H), 1.71-1.76 (m, 4H), 1.51 (d, J = 6.4 Hz, 4H) 1.25-1.28 (m, 2H).
Example 4: synthesis of [ 7-oxo-7- (4-fluoroanilino) ] heptyl phosphoric acid (5d)
The procedure is as in example 1, the aniline being replaced by para-fluoroaniline, and the product being a white solid in 81.8% yield.1HNMR (400 M, CDCl3) δ7.63 (s, 1H), 7.44-7.44 (m, 2H), 7.00 (t, J = 8.8 Hz, 2H), 2.36 (t, J = 7.2 Hz, 2H), 2.29 (t, J = 7.6 Hz, 1H), 1.68-1.74 (m, 3H), 1.49 (d, J = 6.4 Hz, 3H), 1.24 (t, J = 6.4 Hz, 2H), 1.18 (d, J = 6.0 Hz, 1H).
Example 5: HDAC enzyme Activity test assay
The procedure was carried out using a commercially available HDAC enzyme assay kit (BPS Bioscience). The compound was first dissolved in 100% DMSO, then diluted with a buffer in a kit to a concentration of 25, 10, 5, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001. mu.M, and added to a 96-well plate, then 15. mu.L of Hela nuclear extract (15. mu.L of buffer was added to each well of the control group) was added to the reaction well plate, and after 15 min of reaction at room temperature, 10. mu.L of fluorogenic substrate solution was added to start the reaction, the final concentration of HDACs protein in the reaction was 6 nM, the final concentration of tryptin was 0.05. mu.M, and the final concentration of Ac-peptide was 8. mu.M, and after 1 hour of reaction at room temperature in the dark, the fluorescence intensity (emission wavelength 355 nM, absorption wavelength 460 nM) was measured with a microplate reader to calculate the inhibition ratio. Specific results are shown in table 1.
TABLE 1 HDACs inhibitory Activity results (IC) for representative Compounds of interest 5a-d synthesized according to the invention50, nM)
| Compounds | IC50 |
| 5a | 169 |
| 5b | 192 |
| 5c | 246 |
| 5d | 295 |
The above experimental results show that: the synthesized compound shows a strong inhibition effect on the inhibition activity of HDACs enzyme.
Example 6: antitumor Activity test of phosphoric acid Compounds
The breast cancer MCF-7, MDA-MB-231 and the normal epithelial cells MCF-10A of the breast are cultured in a DMEM liquid medium containing 10 percent fetal calf serum and phenol red. When the cell density reaches 80-90%, digesting the cells, and suspending the cells in a phenol red-free DMEM medium containing 10% fetal calf serumSpread to 96 well cell culture plates. After the cells are completely attached to the wall, the original culture solution is discarded, and 100 mul of fresh compound solution prepared by DMEM medium containing 10% fetal calf serum is added into each hole, wherein the compound concentration gradient is as follows: 1X 10-8 M, 1×10-7 M, 5×10-7 M, 1×10-6 M, 1×10-5 M, 5×10-5M, 1×10-4 And M. After 3 days of drug treatment, the plates were removed and 20. mu.L of 5 mg/mL MTT medium was added to each well and placed at 37oC、5% CO2Incubate in the incubator for 4 hours. After that, the liquid was aspirated from each well, and then 100. mu.L of Dimethylsulfoxide (DMSO) was added to each well, and the mixture was shaken on a micro-stirrer for 15 minutes to dissolve the crystals sufficiently. And (3) reading a plate on a microplate reader to test the absorbance value (OD) of each hole, and selecting the wavelength at 490 nm as the dominant wavelength and the wavelength at 630 nm as the reference wavelength. The growth inhibition of tumor cells by different drug concentrations was calculated as follows:
performing linear regression analysis on the concentration of the drug by using the inhibition rate, and calculating IC by using a linear equation50The specific results are shown in Table 2.
TABLE 2 results of MCF-7, MDA-MB-231 and MCF-10A cytostatic Activity (IC) of representative Compounds of interest 5a-d synthesized according to the invention50, μM)
| Compounds | MCF-7 | MDA-MB-231 | MCF-10A |
| 5a | 6.9 | 5.5 | > 100 |
| 5b | 7.5 | 6.2 | > 100 |
| 5c | 10.8 | 9.3 | > 100 |
| 5d | 14.3 | 7.6 | > 100 |
The above experimental results show that: the synthesized compound shows good anti-breast cancer activity not only for hormone-dependent (MCF-7) breast cancer, but also for non-hormone-dependent (MDA-MB-231) breast cancer. Compound 5a (IC)50 = 5.5 μ M) exhibited the strongest inhibitory activity against non-hormone dependent (MDA-MB-231) breast cancer.
Claims (1)
1. A method for preparing a phosphate compound having HDAC inhibitory activity, comprising the steps of:
(1) dissolving aniline, p-toluidine, p-anisidine or p-fluoroaniline and 6-heptenoic acid in dichloromethane, and then adding 2- (7-azobenzotriazol)N,N,N',N' -tetramethyluronium hexafluorophosphate and N, N-diisopropylethylamine, stirred at room temperature for 12 hours; after the reaction was complete, saturated NaHCO was added3Solution, dichloromethane extraction, anhydrous Na2SO4Drying, evaporating dichloromethane to obtain crude product, and purifying by column chromatography to obtain compound 3a, 3b, 3c or 3 d; aniline, p-toluidine, p-anisidine or p-fluoroaniline with 6-heptenoic acid, 2- (7-azobenzotriazol)N,N,N',N' -tetramethyluronium hexafluorophosphate and N, N-diisopropylethylamine in a mass ratio of 1: 1.2: 1.3: 3; wherein the structural formula of compound 3a, 3b, 3c or 3d is as follows:
(2) dissolving the compound 3a, 3b, 3c or 3d inN,N-dimethylformamide, adding K2CO3And dibenzyl phosphite, heating to 50 ℃ and reacting for 2 hours; after the reaction is finished, 5% citric acid solution is added, ethyl acetate is used for extraction, and anhydrous Na2SO4Drying, evaporating to remove ethyl acetate to obtain crude product, and purifying by column chromatography to obtain compound 4a, 4b, 4c or 4 d; compounds 3a, 3b, 3c or 3d with K2CO3And dibenzyl phosphite in a mass ratio of 1: 2: 1.6; wherein the structural formula of compound 4a, 4b, 4c or 4d is as follows:
(3) mixing the compound 4a, 4b, 4c or 4d with 6M HCl, heating to 50 ℃ and reacting for 12 hours; distilling under reduced pressure to remove newly generated benzyl alcohol, extracting with ethyl acetate, and collecting anhydrous Na2SO4Drying, evaporating to remove ethyl acetate to obtain crude product, and purifying by column chromatography to obtain phosphoric acid compounds 5a, 5b, 5c or 5d with HDAC inhibitory activity; the mass ratio of compound 4a, 4b, 4c or 4d to 6M hydrochloric acid is 1: 1.7; the structural formula of compound 5a, 5b, 5c or 5d is as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911213773.7A CN111116647B (en) | 2019-12-02 | 2019-12-02 | Phosphoric acid compound with HDAC (Histone deacetylase) inhibitory activity as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911213773.7A CN111116647B (en) | 2019-12-02 | 2019-12-02 | Phosphoric acid compound with HDAC (Histone deacetylase) inhibitory activity as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111116647A CN111116647A (en) | 2020-05-08 |
| CN111116647B true CN111116647B (en) | 2021-08-24 |
Family
ID=70496657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911213773.7A Active CN111116647B (en) | 2019-12-02 | 2019-12-02 | Phosphoric acid compound with HDAC (Histone deacetylase) inhibitory activity as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111116647B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1699383A (en) * | 2000-03-08 | 2005-11-23 | 症变治疗公司 | Novel aryl fructose-1,6-bisphosphatase inhibitors |
| CN109705165A (en) * | 2019-01-28 | 2019-05-03 | 东北林业大学 | A kind of synthesis of high purity dicyclo phosphonate ester and purification process |
-
2019
- 2019-12-02 CN CN201911213773.7A patent/CN111116647B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1699383A (en) * | 2000-03-08 | 2005-11-23 | 症变治疗公司 | Novel aryl fructose-1,6-bisphosphatase inhibitors |
| CN109705165A (en) * | 2019-01-28 | 2019-05-03 | 东北林业大学 | A kind of synthesis of high purity dicyclo phosphonate ester and purification process |
Non-Patent Citations (4)
| Title |
|---|
| "Exploring DOXP-reductoisomerase binding limits using phosphonatedN-aryl andN-heteroarylcarboxamides as DXR inhibitors";Taryn Bodill et al.,;《Bioorganic & Medicinal Chemistry》;20130507;第21卷(第14期);第4332-4341页 * |
| "Synthesis and Biological Properties of α-Thymidine 5"-Aryl Phosphonates";M. A. Ivanov et al.,;《RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY》;20131114;第39卷(第6期);第718-727页 * |
| "Synthesis and inhibitory activity of acetamidophosphonic acids against metallo-β-lactamases";Yi-Lin Zhang et al.,;《Phosphorus, Sulfur, and Silicon and the Related Elements》;20160825;第192卷(第1期);第1-5页 * |
| "Synthetic Fosmidomycin Analogues with Altered Chelating Moieties Do Not Inhibit 1-Deoxy-D-xylulose 5-phosphate Reductoisomerase or Plasmodium falciparum GrowthIn Vitro";R. Chofor et al.,;《Molecules》;20140224;第19卷(第2期);第2571-2587页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111116647A (en) | 2020-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108524482B (en) | Use of 2- (substituted phenylamino) benzoic acid FTO inhibitors for treating leukemia | |
| CN1950376A (en) | Curcumol derivatives, compositions comprising the same and use in manufacture of medicament | |
| JP2003535078A (en) | Indole derivatives with vascular damage activity | |
| CN104169261A (en) | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use | |
| RU2417217C2 (en) | Salt clusters of ammonium salt and mineral salt with dibasic acid anions which are resistant and stable during storage and synthesis method thereof | |
| WO2020011020A1 (en) | Mefatinib composition, related compound, preparation method therefor and use thereof | |
| US20200165272A1 (en) | Borate compound, and synthesis method therefor and uses thereof | |
| CN111116647B (en) | Phosphoric acid compound with HDAC (Histone deacetylase) inhibitory activity as well as preparation method and application thereof | |
| JP2005532280A (en) | Compound | |
| KR101748229B1 (en) | 2,2'-bis-thiazole-based compounds, preparation method therefor and use thereof | |
| CN109988110B (en) | 4-phenoxy quinoline sulfonylurea compound, intermediate for synthesizing the compound and its preparation method and use | |
| JP2013503829A (en) | Novel multifunctional peptidase inhibitors, especially for use in medicine | |
| CN108752412B (en) | Boswellic acid derivatives and their use | |
| CN109516926B (en) | Preparation and application of piperlonguminine derivative | |
| CN101347412B (en) | Amifostine trihydrate crystal lyophilized preparation and method of preparing the same | |
| CN102477001B (en) | Benzamide histone deacetylase inhibitor | |
| CN113735830A (en) | Hydroximic acid derivatives and application thereof | |
| CN102060875B (en) | Quinazoline derivative, and preparation method and application thereof | |
| CN110041353A (en) | A kind of new boric acid salicylate analog derivative and its pharmaceutical composition | |
| CN104262277A (en) | Nitro containing and halogen benzene substituted 1H-tetrazole-1-acetic acid structure, and preparation method and use thereof | |
| CN109438525B (en) | Compound with chemotherapy and phototherapy antitumor effects and preparation method and application thereof | |
| CN110194743B (en) | Phenyl (3-methoxy-4- (4-methyl-1H-imidazole-1-yl) phenyl) ketone compound | |
| JPS6032631B2 (en) | r-pyridone compounds, their production methods, and agricultural drugs comprising these compounds | |
| CN109232662B (en) | Compound with anti-tumor effect and preparation method and application thereof | |
| CN108261414B (en) | A kind of pharmaceutical composition for treating lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |